CMS Sees No "Systemic" Problems From Cancer Rx Payment Cuts
This article was originally published in The Pink Sheet Daily
Incoming Centers for Medicare & Medicaid Services Administrator McClellan says the agency will "closely" monitor whether beneficiary access is impacted by reimbursement changes for Part B drugs.
You may also be interested in...
Camptosar and Avonex will also receive higher reimbursements. Changes reflect data submitted by manufacturers under AWP "exceptions" process.
Major tasks facing the new Centers for Medicare & Medicaid Services chief include rolling out the Medicare Rx discount card program by May and drafting rules for the full drug benefit.
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.